Abu DhabiUnited Arab Emirates, June 19, 2023 /PRNewswire/ — Ministry of Health — Abu Dhabi (DoH), the regulatory body for the healthcare industry in the emirate, has signed a Memorandum of Understanding (MoU) with AbbVie Biopharmaceutical and M42 to strengthen collaborative efforts in customizing personalized medicine and genomics Abu Dhabis capital united arab emirates (United Arab Emirates). M42 is a first-of-its-kind technology-enabled integrated healthcare company formed from the merger of G42 Healthcare and Mubadala Health.
The MOU is signed by Dr. Asma MannayExecutive Director, Center for Research and Innovation, Department of Health – Abu Dhabi (Ministry of Health), Francesco RedivoSenior Director of G42 Healthcare, an M42 company, and HaradarGulf & Levant, Medical Director, AbbVie Biopharmaceuticals, AbbVie Bioresearch Center boston.
this The three parties aim to advance the application of precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. DoH seeks to advance research that contributes to policy changes and implementation of guidelines that will bring innovative approaches in healthcare to a wider range of patients.
The strategic collaboration aims to maximize the UAE’s unique genomics program and translate scientific advancements into tangible patient benefits, with a focus on precision medicine tailored to individual needs.
PhD Asma MannayExecutive Director, Center for Research and Innovation, Department of Health – Abu Dhabi (Ministry of Health), “There is no doubt that personalized medicine and genomics have the transformative potential to reshape healthcare delivery and improve outcomes,” said Dr. Abu Dhabi Continuing to harness the power of these fields to usher in a new era of healthcare, where each patient’s journey is guided by their own genetic blueprint, improving quality of life and creating a brighter future for generations to come. During our participation in BIO 2023, we are proud to witness yet another collaboration with a renowned partner from the biopharmaceutical industry. “
Hassan SabahGeneral ManagerAbbVie Gulf & Levant Said: “This partnership aims to advance precision medicine in diagnosis and treatment to help a wider range of patients in the UAE gain access to innovative treatments. We are working to launch several initiatives to support research and clinical trials, and to develop innovative solutions to effectively Address local and regional health needs, challenges and burdens.”
As part of its preventive health care efforts, Abu Dhabi Launched the region’s first personalized precision medicine program for oncology in 2022. The program integrates predictive, personalized and precision medicine using genomics to transform diagnosis, medication and prevention, tailored to an individual’s specific needs.
Francesco RedivoSenior Director of G42 Healthcare, M42 Company said, “I am proud to witness how our vision of personalized healthcare is moving forward as we strengthen our commitment to partner with like-minded pharmaceutical companies such as AbbVie, which is known for discovering and delivering innovative medicines and solutions to improve people’s lives. Our collaboration will build on joint efforts to develop innovative solutions around access to care by leveraging real-world evidence capabilities, and by maximizing the potential of the UAE Genome Initiative, Advancing precision medicine by translating scientific advances into tangible patient benefits.”
To learn more, visit: https://www.doh.gov.ae/en/Abu-Dhabi-a-regional-life-science-hub
About the Department of Health – Abu Dhabi (Ministry of Health):
Department of Health – (DoH) is the regulatory body for the healthcare sector in the emirate Abu Dhabi And ensure excellence in healthcare by monitoring the health of the population. The DoH defines the health system’s strategy, monitors and analyzes the health status of the population and the performance of the system. In addition, the DoH develops the health system’s regulatory framework, examines regulations, enforces standards, and encourages the adoption of world-class best practices and performance targets for all healthcare providers in the emirate. DoH also promotes programs to increase awareness and adoption of healthy living standards among Emirate residents Abu Dhabi In addition to regulating the scope of services, premiums and reimbursement rates of the health system.
View original content to download multimedia:https://www.prnewswire.com/news-releases/department-of-health–abu-dhabi-m42-and-abbvie-enter-a-strategic-partnership-to-advance-personalized-medicine-and-genomics -301854543.html
Source Department of Health – Abu Dhabi